Skip to content

Nasdaq · CIK 0001808898

BNTC Benitec Biopharma Inc.

Insider trading from SEC Form 4. Last filing Apr 2, 2025. Close $8.87 on Oct 9, 2026, +1% from the 52-week low and -46% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company

Price and insider trades, last year

BNTCOct 9, 2026 · close 8.87

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Benitec Biopharma Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
31WeakSuvretta Capital Management, LLC
director, owner
buy
$212k
16,497 shares
+0%+60% from low-23% from high
47ModerateSuvretta Capital Management, LLC
director, owner
buy
$12M
900,000 shares
+11%+72% from low-17% from high
33WeakSuvretta Capital Management, LLC
director, owner
buy
$527k
47,520 shares
+1%-
31WeakSuvretta Capital Management, LLC
director, owner
buy
$403k
42,000 shares
+1%-
26WeakSuvretta Capital Management, LLC
director, owner
buy
$417k
41,436 shares
+1%-

Transactions

The last 26 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Mar 31, 2025Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+9,503$12.63$120k8,802,748Apr 2, 2025
Mar 31, 2025Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+1,267$12.63$16k1,068,031Apr 2, 2025
Mar 31, 2025Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+5,057$13.22$67k8,807,805Apr 2, 2025
Mar 31, 2025Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+670$13.22$8,8571,068,701Apr 2, 2025
Mar 26, 2025Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+793,800$13.00$10M8,793,245Mar 28, 2025
Mar 26, 2025Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+106,200$13.00$1.4M1,066,764Mar 28, 2025
Mar 12, 2025J Kevin Buchi
director
GGift
Common Stock
-103,626$0.00$0284Mar 13, 2025
Mar 12, 2025J Kevin Buchi
director
GGift
Common Stockindirect: By Trust
+103,626$0.00$0103,626Mar 13, 2025
Feb 27, 2025J Kevin Buchi
director
MOption exercise
Common Stock
+51,813$3.86$200k103,910Mar 3, 2025
Feb 27, 2025J Kevin Buchi
director
MOption exercise
Common Warrants (right to buy)derivative
-51,813$0.00$00Mar 3, 2025
Dec 23, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+24,360$10.98$267k7,981,725Dec 26, 2024
Dec 23, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+3,142$10.98$34k958,266Dec 26, 2024
Dec 24, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+17,730$11.25$199k7,999,455Dec 26, 2024
Dec 24, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+2,288$11.25$26k960,554Dec 26, 2024
Dec 9, 2024J Kevin Buchi
director
AGrant or award
Options (right to buy)derivative
+35,000$0.00$035,000Dec 11, 2024
Dec 9, 2024Jerel A. Banks
Chief Executive Officer
AGrant or award
Options (right to buy)derivative
+2,310,000$0.00$02,310,000Dec 11, 2024
Dec 9, 2024Megan Boston
Executive Director
AGrant or award
Options (right to buy)derivative
+720,000$0.00$0720,000Dec 11, 2024
Dec 9, 2024Edward F Smith
director
AGrant or award
Options (right to buy)derivative
+35,000$0.00$035,000Dec 11, 2024
Dec 9, 2024Peter Francis
director
AGrant or award
Options (right to buy)derivative
+35,000$0.00$035,000Dec 11, 2024
Dec 9, 2024Kishan Mehta
director
AGrant or award
Options (right to buy)derivative
+35,000$0.00$035,000Dec 11, 2024
Dec 3, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+37,190$9.60$357k7,957,365Dec 5, 2024
Dec 3, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+4,810$9.60$46k955,124Dec 5, 2024
Nov 19, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+12,430$9.73$121k7,895,815Nov 21, 2024
Nov 19, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+1,570$9.73$15k947,238Nov 21, 2024
Nov 20, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+24,360$10.22$249k7,920,175Nov 21, 2024
Nov 20, 2024Suvretta Capital Management, LLC
director, owner
POpen-market purchase
Common stock, par value $0.0001 per shareindirect: See footnotes
+3,076$10.22$31k950,314Nov 21, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

BNTC insider trading: Benitec Biopharma Inc. | InsiderTell